Overview
The Ministry of Commerce & Industry announced that India’s pharmaceutical sector, valued at about $60 billion, can double in size within the next five years. Union Minister Piyush Goyal invited global pharma companies to join India’s shift from generic medicines to innovation‑driven products while keeping drugs affordable.
Key Developments
- Invitation to global firms at the GDRC 2026 and IPHEX 2026.
- India aims to move beyond generics, focusing on innovative medicines, biopharma, and clinical‑trial collaborations.
- Emphasis on three pillars: trust, innovation, and partnerships.
- Highlight of India’s strong regulatory framework – alignment with global GMP standards and the highest number of US FDA‑approved plants outside the United States.
- Reference to India’s robust trade network: nine recent Free Trade Agreements covering over 50 countries, offering zero‑duty access for many pharma products.
- Commitment to affordable medicines – generics constitute 80‑90% of US volume but only 10‑15% of value, underscoring cost advantage.
Important Facts
• India’s economy grew 7.7 % (constant prices) in FY 2025‑26 despite global turbulence (Ukraine, West Asia, US tariffs).
• Around 65‑70 % of WHO vaccine requirements are sourced from India.
• India hosts 10 of the world’s 25 largest generic manufacturers and the most US FDA‑approved pharma plants outside the US.
• Patent filings have risen by nearly 100 % in recent years, reflecting growing R&D activity.
• The government announced a $10 billion innovation fund covering pharma and other sectors.
UPSC Relevance
The announcement touches upon several GS topics: GS1 – India’s historical role in global health (ancient “Sarve Santu Niramaya” philosophy); GS2 – policy decisions of the Union Minister and trade negotiations; GS3 – pharma industry’s contribution to GDP, trade‑related FTAs, and innovation ecosystem; GS4 – ethical dimension of equitable access to medicines and global responsibility post‑COVID‑19.
Way Forward
• Strengthen R&D infrastructure through the Biopharma Shakti programme and the $10 billion fund.
• Leverage FTAs to secure market access for innovative drugs while maintaining zero‑duty preferences for generics.
• Encourage foreign pharma firms to set up R&D, clinical‑trial, and manufacturing units in India, tapping the large domestic market of 1.4 billion people.
• Continue aligning GMP and regulatory standards with global benchmarks to build trust.
• Promote public‑private partnerships that ensure affordable pricing, especially for low‑income nations.